Pamela N. Munster
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (55)
Year:
2026
Year:
2026
Year:
2026
PURPOSE Continued improvement in outcomes is needed for advanced cutaneous squamous cell carcinoma (cSCC). Methods Alliance A091802 is a randomized phase II trial of avelumab (800 mg IV once every 2 weeks) plus cetuximab (500 mg/m 2 IV once every 2 weeks) versus avelumab alone once every 2 weeks for up to 2 years. Cetuximab was given for 1 year in the avelumab + cetuximab arm. Crossover at progression to avelumab + cetuximab was allowed. Randomization was 1:1, stratified by PD-L1 and HIV status. Patients had distant metastatic or unresectable locally advanced cSCC, were anti–PD-1/PD-L1 monoclonal antibody–naive, had no previous cetuximab in the advanced setting, had an Eastern Cooperative Oncology Group performance status of 0-2, and could be HIV+ (CD4 >200, viral load <200). Patients with chronic lymphocytic leukemia, immunosuppression, or active autoimmune diseases were excluded. The primary end point was progression-free survival (PFS; null hypothesis: median = 12 months v alternative hypothesis: 21 months or a 75% improvement, power of 80% with one-sided alpha .2, n = 57, 37 PFS events required). Secondary end points were overall survival, objective response rates (ORRs), clinical benefit rate, and toxicity. RESULTS Sixty patients were enrolled; 57 patients were evaluable. The median age was 72 years, all were HIV–; 75.4% was PD-L1+, 84.2% had head/neck origin, 47.4% had distant metastasis, and there were no differences in baseline characteristics by arm. Avelumab + cetuximab significantly improved PFS versus avelumab (median, 11.1 [7.6-not reached (NR)] v 3.0 months [2.7-13.6] hazard ratio, 0.48 [95% CI, 0.23 to 0.97], P = .018). Avelumab patients who crossed over (n = 9) to combination had a median PFS after crossover of 11.3 months (5.8-NR). The confirmed ORR was 27.6% with avelumab + cetuximab and 21.4% with avelumab. Grade 3 treatment-related adverse events occurred in 48.3% and 21.5% of patients with avelumab + cetuximab (most common: rash [20.7%], infusion reaction [20.7%]) and avelumab, respectively. CONCLUSION Avelumab + cetuximab significantly improved PFS versus avelumab alone in patients with advanced cSCC. Alliance A091802 supports a larger confirmatory study with the combination of cetuximab and PD-1:PD-(L)1 blockade.
Year:
2025
11507 Background: Advanced uterine leiomyosarcoma (uLMS) is an aggressive malignancy with poor prognosis. Standard-of-care treatments, including trabectedin (Tb) or pazopanib (P), provide median progression-free survival (PFS) of 3-4 months (mo) and objective response rates (ORR) of ~11%. Homologous recombination deficiency (HRD) in a subset of uLMS supports the use of PARP inhibitors combined with DNA-damaging agents. Preclinical studies demonstrated synergistic activity of olaparib and temozolomide (T+O), and a prior single-arm Phase II study of T+O showed promising efficacy independent of an established biomarker, warranting further investigation in a randomized setting. Methods: Alliance A092104 is a Phase II/III trial evaluating olaparib (200 mg BID) plus temozolomide (75 mg/m² daily, days 1-7, every 21 days) versus investigator’s choice of Tb or P in patients (pts) with advanced uLMS who progressed on ≥2 prior systemic therapies. Stratification factors included ECOG (0-1 vs. 2) and prior lines (2 vs. ≥3). The Phase II (Phase III) primary endpoint was PFS (OS), with a planned suspension of accrual at the end of Phase II. A total of 70 evaluable pts (58 PFS events) were needed to detect an improvement in PFS from 4 vs. 8 mo with power of 90% and 1-sided type I error of 10%, with futility assessed after 29 PFS events. Upon meeting the Phase II futility threshold for PFS, the trial was permanently closed. Data were released from the data and safety monitoring board. Pts continue to be followed for outcomes. Results: 74 pts enrolled (Arm 1: T+O, n = 37; Arm 2: investigator’s choice, n = 37 (Tb, 18; P, 13; 6 pts did not start treatment). The arms were balanced for baseline demographics except race, with the T+O arm having a higher proportion of black/African American (29.7% vs. 16.2%). 21 pts remain on treatment. Hematologic adverse events (AEs) were more frequent in the T+O arm, with Grade 4 neutropenia (19.5%) and thrombocytopenia (8.3%) both managed by dose reductions. Non-hematologic Grade 3 AEs were higher in the investigator’s choice arm (45.2% vs. 13.9%). No Grade 5 AEs were reported. In the first 70 pts, with a median follow-up of 5.9 mo, and 39 total PFS events, the median PFS was 3.2 mo (95% CI: 2.0-NE) for T+O versus 5.6 mo (95% CI: 2.8-NE) for investigator’s choice (HR = 1.00; 95% CI: 0.60-2.17; 1-sided stratified log rank p = 0.50). Within Arm 2, the median PFS for Tb and P were respectively 5.6 (95% CI: 3.1-NE) and 3.8 (95% CI: 1.5-NE) mo. 3 pts in the T+0 arm and 1 patient in the investigator’s choice arm (Tb) had a confirmed partial response. Conclusions: The trial did not meet its primary endpoint of PFS in Phase II. This suggests that a biomarker may be needed before there is further exploration of PARP inhibitor-based regimens in uLMS. Overall survival and analysis of tissue-based biomarkers will be presented. Clinical trial information: NCT05432791 .
Year:
2025
Purpose: PI3K/mTOR pathway activation drives oncogenesis and progression of many cancers. RMC-5552 is a bi-steric, mTOR complex 1 (mTORC1)-selective inhibitor that potently inhibits phosphorylation of key mTORC1 substrates eukaryotic initiation factor 4E-binding protein-1 and S6 kinase and exhibits selectivity for mTORC1 over mTORC2. In this study, we report results from a first-in-human, dose-escalation study of RMC-5552 in patients with advanced solid tumors (NCT04774952). Patients and Methods: The safety, tolerability, pharmacokinetics, and preliminary activity of RMC-5552 (1.6–16 mg intravenous infusion weekly) were evaluated in 57 patients. Results: The most common treatment-related adverse events were mucositis (49%), nausea (44%), and fatigue (42%). Consistent with mTORC1 selectivity, treatment-related hyperglycemia incidence was generally low (4%) and not dose limiting. Additionally, we tested potential prophylaxis with tacrolimus mouthwash (TM), which was predicted to block the mechanism of action of RMC-5552 locally and alleviate treatment-related oral mucositis. Between 8- and 12-mg dosing, mucositis was 65% without TM versus 31% with TM. In this study, the disease control rate was 64%, and one patient with PTEN- and PIK3CA-altered endometrial cancer had a complete response and treatment was ongoing for >6 months as of the June 2024 data cut. Clearance of PI3K/mTOR pathway variants among ctDNA was observed. Conclusions: The success of TM-mediated prophylaxis and the clearance of selected variants in ctDNA are concordant with selective, on-mechanism, antitumor activity following RMC-5552 treatment. These data show that RMC-5552, the first bi-steric mTORC1-selective inhibitor in the clinic, is active at tolerable doses and that selective inhibition of mTORC1 alleviates mTORC2-mediated hyperglycemia, overcoming a key limitation of prior mTOR inhibitors.
Year:
2025
Talimogene laherparepvec (T-VEC) is an oncolytic virus that is hypothesized to enhance responses to systemic therapy. This Phase 1b trial evaluated the safety and efficacy of intratumoral T-VEC plus chemotherapy (CT) or endocrine therapy (ET) for patients with hormone receptor positive (HR + )/HER2- and triple negative (TN) advanced breast cancer (ABC) with injectable locoregional/chest wall disease. The primary endpoint was safety/tolerability. Secondary endpoints were objective response rate by irRECIST 1.1 and clinical assessment of local response. 19 patients enrolled (9 HR + /HER2-; 10 TN; median two lines of prior CT). Intratumoral T-VEC was administered with the following partners: gemcitabine/carboplatin ( n = 8), nab-paclitaxel ( n = 7), paclitaxel ( n = 2), or ET ( n = 2). Eight patients in the T-VEC + gemcitabine/carboplatin arm were formally evaluated for dose limiting toxicities (DLTs) based on pre-specified protocol criteria, and one DLT (grade 3 neutropenia leading to carboplatin dose reduction) was identified. Response per irRECIST 1.1 was evaluated in 16 patients: partial response ( n = 2, 12.5%), stable disease ( n = 7, 43.8%), progressive disease ( n = 7, 43.8%). Patients with higher pre-treatment tumor infiltrating lymphocytes (TILs) were more likely to respond, and clinical responders had induction of Ki-67 in multiple peripheral myeloid populations. In conclusion, the addition of intratumoral T-VEC to CT or ET was safe in patients with ABC and injectable locoregional disease, supporting the continued investigation of direct intratumoral immunomodulatory strategies that can enhance local and systemic immune responses. NCT03554044.
Year:
2025
TPS3183 Background: Patients with germline or somatic HRR pathway mutations often develop resistance despite initial response. Overlapping toxicities hinder combination strategies in breast, ovarian, prostate, and pancreatic cancers, creating a need for safer and more effective approaches. Preclinical studies have shown that DNMT inhibition enhances PARP inhibitor efficacy by promoting PARP trapping on DNA. This phase I study aims to assess the safety and tolerability of olaparib and AST727 in HRR-mutated patients and establish the RP2D for a phase II trial, to be supported by the NCI ComboMatch program. Correlative studies include the creation of PDX and organoid models for ex vivo analysis of therapy response. Methods: Further studies include cfDNA and tumor tissue assessment to elucidate mechanisms of resistance (reversion mutations, epigenetic markers) and PD markers of HR pathway modulation. Rad51 foci will be measured to determine DNA repair function and CHIP assays (clonal hematopoiesis of indeterminate potential) to study the differential rate of CHIP as an early event in the evolution of AML/MDS. Trial Design: This is a single center phase I/Ib clinical trial evaluating the combination of olaparib and ASTX727 (an oral formulation of decitabine with cedazuridine, a cytidine deaminase inhibitor that allows for oral administration). All participant enrollment and study participation will be conducted at UCSF as single site trial with collaboration from other centers for correlative/exploratory objectives. The phase I dose escalation portion will follow a standard 3+3 design for enrollment and will include adults with advanced/metastatic solid tumor malignancies with germline or somatic mutations in the HRR pathway (i.e., BRCA1/2, PALB2, ATM, and/or CHEK2 mutations). Patients will be treated in 2 escalating cohorts with a 12 patient phase Ib dose expansion in the same population. At least 6 of 12 expansion patients must have germline HRD mutations. Key Eligibility: The participant must have histologically confirmed advanced solid tumors with a germline and/or somatic mutation in one or more of the following genes: BRCA1/2, PALB2, ATM, and/or CHEK2. Patients must have adequate organ function and recovered from prior treatment associated toxicities. Prior treatment with PARP inhibitors is allowed if the participant has not required dose reductions or delays due to toxicity. Participants with treated brain metastases are eligible if follow-up brain imaging shows no evidence of progression for at least 4 weeks. Individuals with a prior or concurrent malignancy are eligible, however participants diagnosed with MDS or AML are excluded from the study. Trial Status: The study is ongoing and 4 patients have been enrolled to date. Clinical trial information: NCT06177171 .
Year:
2025
6002 Background: There is a need for continued improvement in outcomes with systemic therapy for advanced cSCC. Pre-clinical data suggest immunologic synergy between IgG1 mAb therapy targeting EGFR and PD-1:PD-(L)1 blockade. Methods: Alliance A091802 is a randomized phase II trial of avelumab (AV) (800 mg) plus cetuximab (C) (500 mg/m2) vs. AV alone every 2 weeks for up to 2 years (yrs). C was given for 1 yr in the AV+C arm. Crossover at progression to AV+C was allowed in the AV arm. Randomization was 1:1 and stratified by PD-L1 [+(>1%) vs. -] and HIV status (+ vs. -). Eligible patients (pts) had distant metastatic or unresectable locally advanced cSCC, anti-PD-1/PD-L1 mAb naive, no prior cetuximab in the advanced setting, ECOG PS 0-2, HIV+ if CD4 >200 and VL 3 in 48.3% and 21.5% of pts in the AV+C [most common G3 TRAEs were rash (20.7%) and infusion-related reaction (20.7%)] and AV arms, respectively. There were no G5 events. Outcomes after crossover and by PD-L1 status will be presented subsequently. Conclusions: Avelumab plus cetuximab significantly improved PFS vs. avelumab alone in advanced cSCC pts, without unexpected toxicity. Alliance A091802 supports a larger confirmatory study with combination cetuximab and PD-1:PD-(L)1 blockade. Support: U10CA180821, U10CA180882, U24CA196171; U10CA180868 (NRG Oncology); U10CA180888 (SWOG); https://acknowledgments.alliancefound.org . EMD Serono CrossRef Funder ID: 10.13039/100004755. Clinical trial information: NCT03944941 .
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (32)
Anwaar Saeed
University of Pittsburgh
Shivaani Kummar
Oregon Health & Science University
Naoto Ueno
Professor of Medicine
University of Hawai'i Cancer Center
Ludimila Cavalcante
Associate Professor, Director, Sarcoma Medical Oncology, Associate Director, Developmental Therapeutics
University of Virginia
Benedito A. Carneiro
-
Wendy Rathmell
Professor, Department Chair
Vanderbilt University Medical Center
Emily K. Bergsland
University of California, San Francisco
Nikolaos Trikalinos
Assistant Professor
Washington University in St. Louis
Teresa Lee
Assistant Professor
Fox Chase Cancer Center
Alan Ashworth
University of California, San Francisco
Niharika Mettu
Duke University
Nicholas Iannotti
-
Vaibhav Sahai
University of Michigan
Timothy Burns
Professor
University of Pittsburgh
Steven John O'Day
Chief Medical Officer
-
John Kirkwood
Distinguished Service Professor of Medicine
University of Pittsburgh
Devalingam Mahalingam
Associate Professor of Medicine
Northwestern University Feinberg School of Medicine
Patricia LoRusso
Yale University
Vaia Florou
Associate Professor
Huntsman Cancer Institute
Andrés Cervantes
Professor of Medicine
University of Valencia
Ari Rosenberg
University of Chicago Medicine
Mark Yarchoan
Johns Hopkins University
Susanna Ulahannan
Associate Professor
University of Oklahoma Health Sciences Center
Paul Swiecicki
University of Michigan
hu li
Professor
Mayo Clinic Minnesota
Razelle Kurzrock
-
Christopher T. Chen
Stanford University School of Medicine
Andrew Coveler
Fred Hutchinson Cancer Research Center
R. Donald Harvey
Emory University School of Medicine
Rahul Aggarwal
University of California
Elizabeth Davis
Vanderbilt University Medical Center
Mamta Parikh
Associate Professor
University of California Davis Comprehensive Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.